Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Clinical Endocrinology|May 20, 2011
A prospective study of lymphocyte subpopulations and regulatory T cells in patients with chronic hepatitis C virus infection developing interferon-induced thyroiditisBerta Soldevila, Núria Alonso, Maria J Martínez-Arconada, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2018
CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78)Gemma Aran, Lucía Sanjurjo, Cristina Bárcena, et al.
Antiviral Therapy|July 22, 2006
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological responseDaniel Fuster, Ramon Planas, Juan Gonzalez, et al.
Antiviral Therapy|February 7, 2009
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patientsCristina Tural, Josep Antón Galeras, Ramon Planas, et al.
Hepatology (Baltimore, Md.)|December 29, 2007
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosisAmir A Qamar, Norman D Grace, Roberto J Groszmann, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2017
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver diseaseChristophe Hézode, Piero L Almasio, Stefan Bourgeois, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 14, 2009
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosisAmir A Qamar, Norman D Grace, Roberto J Groszmann, et al.
Plos One|April 1, 2015
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim studyManuel Romero-Gómez, Juan Turnes, Javier Ampuero, et al.
Hepatology (Baltimore, Md.)|June 26, 2010
Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injuryM Isabel Lucena, Elena García-Martín, Raúl J Andrade, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 13, 2014
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysisJose L Calleja, Juan M Pascasio, Belén Ruiz-Antorán, et al.
Pageof 6